Nanotechnology Now

Our NanoNews Digest Sponsors







Heifer International

Wikipedia Affiliate Button


Home > Press > PDS Biotechnology Corporation Signs Worldwide Licensing Agreement with Merck KGaA for Versamune™

Abstract:
PDS Biotechnology Corporation announced today that they have entered into an exclusive worldwide licensing agreement with Merck KGaA, Darmstadt, Germany, for use of PDS Biotechnology's novel Versamune™ nanotechnology platform in two of Merck's investigational antigen-specific cancer immunotherapies currently in pre-clinical development. Merck obtains the rights to utilize the technology with two investigational antigen-specific cancer immunotherapies which are in pre-clinical development.

PDS Biotechnology Corporation Signs Worldwide Licensing Agreement with Merck KGaA for Versamune™

Lawrenceburg, IN | Posted on July 8th, 2012

Dr. Frank Bedu-Addo, Chief Executive of PDS Biotechnology Corporation said, "We are very pleased that Merck which is experienced in the clinical development of cancer immunotherapies would like to utilize the Versamune™ technology. For PDS Biotechnology Corporation, this deal is important since the company's business strategy is focused on a few strategic out-licensing or partnering deals at a preclinical or early clinical stage. This is the stage where companies will be seeking to enhance their pipelines by taking advantage of a new technology that has broad potential applications in clinical research into the treatment and prevention of cancer and infectious diseases."

####

About PDS Biotechnology Corporation
PDS Biotechnology Corporation is a privately held biotechnology company founded to exploit the newly discovered properties of specific synthetic positively charged (cationic) lipids to commercialize a new generation of immunotherapies and vaccines. The proprietary Versamune™ platform nanotechnology, when combined with specific cancer-associated molecules, has been demonstrated to lead to increased tumor regression rates compared to leading clinical adjuvants in pre-clinical cancer models (Cancer Immunology Immunotherapy, 2008, 57: (4) 517-530). The Versamune™ nanotechnology presents a giant step forward in the development of the next generation of immunotherapies. PDS Biotechnology Corporation's lead products are being developed to treat prevalent cancers such as cervical cancer, head and neck cancer and melanoma. The technology is also being applied to the development of vaccines which are designed to protect against pandemic diseases. Visit www.pdsbiotech.com for more information on Versamune™ and products in development.

For more information, please click here

Contacts:
PDS Biotechnology Corporation
500 Industrial Drive
Suite A
Lawrenceburg, IN 47025
Tel: 812-537-0779
Fax: 812-537-1614

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Imec and GLOBALFOUNDRIES collaborate to advance high-density memory technology: STT-MRAM offers enhanced performance and scalability for embedded and standalone applications May 21st, 2013

International survey supports need for built-in water protection on smartphones and tablets May 21st, 2013

Rice unveils method for tailoring optical processors: Arranging nanoparticles in geometric patterns allows for control of light with light May 21st, 2013

Iran to Hold 1st Conference on Applications of Nanotechnology in Energy Industry May 21st, 2013

Nanomedicine

Nanoparticle Delivers Large Protein Complex to Cancer Cell Nucleus May 20th, 2013

Protein 'Passport' Helps Nanoparticles Get Past Immune System May 20th, 2013

Nanoparticle Harnesses Powerful Radiation Therapy for Cancer May 20th, 2013

Elsevier Business Intelligence (EBI) to Host 'IN3 Medical Device 360 Boston,' June 24-26, 2013 May 20th, 2013

Announcements

Imec and GLOBALFOUNDRIES collaborate to advance high-density memory technology: STT-MRAM offers enhanced performance and scalability for embedded and standalone applications May 21st, 2013

International survey supports need for built-in water protection on smartphones and tablets May 21st, 2013

Rice unveils method for tailoring optical processors: Arranging nanoparticles in geometric patterns allows for control of light with light May 21st, 2013

Iran to Hold 1st Conference on Applications of Nanotechnology in Energy Industry May 21st, 2013

Patents/IP/Tech Transfer/Licensing

NanoInk, Inc. Assets To Be Sold May 18th, 2013

HELIOS Program Develops Complete Supply Chain for Integrating Photonics with CMOS Circuit via IC Fabrication Processes May 14th, 2013

Nanotechnology Pioneer Named 'Entrepreneur of the Year': Royal Society of Chemistry honors Chad Mirkin for commercializing innovations May 10th, 2013

Arrowhead Receives Patent Allowance for DPC siRNA Delivery System with Peptide Backbone May 7th, 2013

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More












ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project








abbigliamento uomo
Computer Accessories
© Copyright 1999-2013 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE